Luis A. Diaz, Jr., MD

Dr. Luis A. Diaz, Jr. on Pembrolizumab For MMR-Deficient Colorectal Cancer

July 23rd 2015

Luis A. Diaz, Jr. MD, associate professor of Oncology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, discusses the efficacy of PD-1 inhibitor pembrolizumab (Keytruda) in heavily pretreated colorectal cancer patients with mismatch repair (MMR).